<!DOCTYPE html>
<html>
<head>
<meta http-equiv="X-UA-Compatible" content="IE=Edge" />
<meta charset="utf-8" />
</head>

<body style="margin: 0;">

<div id="p120" style="overflow: hidden; position: relative; background-color: white; width: 908px; height: 1286px;">

<!-- Begin shared CSS values -->
<style class="shared-css" type="text/css" >
.t {
	transform-origin: bottom left;
	z-index: 2;
	position: absolute;
	white-space: pre;
	overflow: visible;
	line-height: 1.5;
}
.text-container {
	white-space: pre;
}
@supports (-webkit-touch-callout: none) {
	.text-container {
		white-space: normal;
	}
}
</style>
<!-- End shared CSS values -->


<!-- Begin inline CSS -->
<style type="text/css" >

#t1_120{left:130px;bottom:1195px;letter-spacing:0.21px;}
#t2_120{left:796px;bottom:1195px;letter-spacing:0.13px;}
#t3_120{left:238px;bottom:1115px;letter-spacing:-0.01px;}
#t4_120{left:238px;bottom:1096px;letter-spacing:-0.01px;}
#t5_120{left:238px;bottom:1076px;letter-spacing:-0.01px;}
#t6_120{left:238px;bottom:1057px;letter-spacing:-0.01px;}
#t7_120{left:415px;bottom:1057px;letter-spacing:-0.01px;}
#t8_120{left:238px;bottom:1037px;letter-spacing:-0.01px;}
#t9_120{left:238px;bottom:1018px;letter-spacing:-0.01px;}
#ta_120{left:238px;bottom:998px;letter-spacing:-0.01px;}
#tb_120{left:238px;bottom:979px;letter-spacing:-0.01px;}
#tc_120{left:238px;bottom:959px;letter-spacing:-0.01px;}
#td_120{left:238px;bottom:940px;letter-spacing:-0.01px;}
#te_120{left:238px;bottom:853px;letter-spacing:-0.01px;}
#tf_120{left:238px;bottom:833px;letter-spacing:-0.01px;}
#tg_120{left:238px;bottom:814px;letter-spacing:-0.01px;}
#th_120{left:238px;bottom:794px;letter-spacing:-0.01px;}
#ti_120{left:238px;bottom:775px;letter-spacing:-0.01px;}
#tj_120{left:238px;bottom:755px;letter-spacing:-0.01px;}
#tk_120{left:238px;bottom:707px;letter-spacing:-0.01px;}
#tl_120{left:238px;bottom:688px;letter-spacing:-0.01px;}
#tm_120{left:238px;bottom:669px;letter-spacing:-0.01px;}
#tn_120{left:238px;bottom:649px;letter-spacing:-0.01px;}
#to_120{left:238px;bottom:601px;letter-spacing:0.1px;}
#tp_120{left:238px;bottom:582px;letter-spacing:0.1px;}
#tq_120{left:238px;bottom:563px;letter-spacing:0.1px;}
#tr_120{left:238px;bottom:543px;letter-spacing:0.11px;}
#ts_120{left:202px;bottom:69px;letter-spacing:0.23px;}

.s0_120{font-size:11px;font-family:NotoSans-Regular_7j-;color:#000;}
.s1_120{font-size:12px;font-family:NotoSans-Regular_7j-;color:#000;}
.s2_120{font-size:13px;font-family:NotoSans-Regular_7j-;color:#000;}
</style>
<!-- End inline CSS -->

<!-- Begin embedded font definitions -->
<style id="fonts120" type="text/css" >

@font-face {
	font-family: NotoSans-Regular_7j-;
	src: url("fonts/NotoSans-Regular_7j-.woff") format("woff");
}

</style>
<!-- End embedded font definitions -->

<!-- Begin page background -->
<div id="pg120Overlay" style="width:100%; height:100%; position:absolute; z-index:1; background-color:rgba(0,0,0,0); -webkit-user-select: none;"></div>
<div id="pg120" style="-webkit-user-select: none;"><object width="908" height="1286" data="120/120.svg" type="image/svg+xml" id="pdf120" style="width:908px; height:1286px; -moz-transform:scale(1); z-index: 0;"></object></div>
<!-- End page background -->


<!-- Begin text definitions (Positioned/styled in CSS) -->
<div class="text-container"><span id="t1_120" class="t s0_120">8.2. Imaging in follow-up </span><span id="t2_120" class="t s1_120">120 </span>
<span id="t3_120" class="t s2_120">Follow-up examination. This particularly applies to carcinomas that were larger than T1 with </span>
<span id="t4_120" class="t s2_120">para- or supraglottic extension. In the case of small glottic carcinomas, endoscopy is superior to </span>
<span id="t5_120" class="t s2_120">imaging, as smaller changes on the mucosal surface cannot be visualized. High-resolution CT is </span>
<span id="t6_120" class="t s2_120">very sensitive in the area of </span><span id="t7_120" class="t s2_120">the larynx and is the method of choice. The lymphatic drainage </span>
<span id="t8_120" class="t s2_120">pathways of the neck can be visualized in the same session in order to detect or exclude </span>
<span id="t9_120" class="t s2_120">metastases. MRI can be advantageous in the question of cartilage infiltration. The time interval </span>
<span id="ta_120" class="t s2_120">for follow-up imaging should be determined depending on the initial tumor category. In the </span>
<span id="tb_120" class="t s2_120">case of larger carcinomas (-T3), the first imaging is recommended 3 months after the end of </span>
<span id="tc_120" class="t s2_120">therapy. If there is an increased risk of distant metastases, a CT of the thorax and abdomen </span>
<span id="td_120" class="t s2_120">must also be performed in the follow-up examination, possibly a PET-CT [417, 418]. </span>
<span id="te_120" class="t s2_120">After definitive radiochemotherapy or radiotherapy with a good clinical response, a contrast- </span>
<span id="tf_120" class="t s2_120">enhanced baseline cross-sectional imaging of the head and neck area can be performed 8-12 </span>
<span id="tg_120" class="t s2_120">weeks after the end of therapy to assess the post-therapeutic local findings. The choice of </span>
<span id="th_120" class="t s2_120">cross-sectional imaging modality (CT, MRI) should be made depending on the initial tumor </span>
<span id="ti_120" class="t s2_120">location and the initial tumor or N category in accordance with the recommendations in the </span>
<span id="tj_120" class="t s2_120">chapter on primary diagnostics. </span>
<span id="tk_120" class="t s2_120">If these examinations indicate a suspicion of locoregional recurrence or residue, distant </span>
<span id="tl_120" class="t s2_120">metastasis or a second tumor, FDG-PET/CT may be considered. There is no evidence that </span>
<span id="tm_120" class="t s2_120">regular chest X-rays or the determination of tumor markers in serum are of any benefit in </span>
<span id="tn_120" class="t s2_120">tumor follow-up. </span>
<span id="to_120" class="t s1_120">In March 2017, the Federal Joint Committee decided in accordance with Section 91 of the Social </span>
<span id="tp_120" class="t s1_120">Security Code (SGB V) that PET/CT for head and neck tumors will be covered by health insurance to </span>
<span id="tq_120" class="t s1_120">avoid invasive procedures such as neck dissection and laryngoscopic biopsy. This applies in </span>
<span id="tr_120" class="t s1_120">particular to patients with laryngeal cancer after primary radiochemotherapy. </span>
<span id="ts_120" class="t s0_120">Â© Oncology Guideline Program | S3 Guideline Laryngeal Carcinoma | Long Version 1.0 | January 2019 </span></div>
<!-- End text definitions -->


</div>
</body>
</html>
